159
Views
5
CrossRef citations to date
0
Altmetric
Patent Evaluation

Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1

ORCID Icon, ORCID Icon, &
Pages 311-314 | Received 23 Jan 2019, Accepted 15 Apr 2019, Published online: 24 Apr 2019
 

ABSTRACT

Introduction: LAG-3 is checkpoint inhibitor in cancer that coordinates the down regulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused on inhibiting the action of LAG-3 and consequently improving the immune response in the various types of cancer. Authors of patent US2018271940 propose a method to eradicate cancer that utilizes the combination of LAG-3Ig and anti-PD-1 or anti-PD-L1 antibodies.

Areas covered: Patent US2018271940 describes a method consisting of the utilization of either a pharmaceutical cocktail containing LAG-3Ig and an anti-PD-1 or anti-PD-L1 antibody for activation of T cells as a potential for the treatment of cancer.

Expert opinion: Data supporting the patent demonstrate the ability of LAG-3Ig and PD-1/PD-L1 to be useful in T cells activation, in addition to the reports showing that LAG-3 and anti-PD-1 and PD-L1 antibodies are therapeutic agents against cancer. Although the proposed methodology is very interesting and promising, further studies are necessary to assess the clinical applicability of the inventions on cancer.

Acknowledgments

We thank the Mexican people for the support, through their taxes, provided for the development of this article.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.